Daehan New Pharm Co. Ltd (054670) — Cash Flow Reinvestment Rate
Daehan New Pharm Co. Ltd (054670) has a Cash Flow Reinvestment Rate of 2.61x as of September 2025, reinvesting ₩11.53 Billion (capex ₩11.53 Billion ) from operating cash flow of ₩4.43 Billion. See 054670 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Daehan New Pharm Co. Ltd Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for Daehan New Pharm Co. Ltd across 12 annual periods. For the full cash flow conversion analysis, see how efficiently does Daehan New Pharm Co. Ltd generate cash.
Annual Cash Flow Reinvestment Rate for Daehan New Pharm Co. Ltd (2011–2024)
Year-by-year capital reinvestment analysis for Daehan New Pharm Co. Ltd. See Daehan New Pharm Co. Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.35x | ₩63.38 Billion | ₩18.95 Billion | ₩34.26 Billion | ▲ +89.1% |
| 2023 | 1.77x | ₩22.23 Billion | ₩12.57 Billion | ₩9.93 Billion | ▲ +141.5% |
| 2022 | 0.73x | ₩10.44 Billion | ₩14.25 Billion | ₩3.51 Billion | ▼ -50.4% |
| 2021 | 1.48x | ₩24.48 Billion | ₩16.58 Billion | ₩10.55 Billion | ▲ +30.2% |
| 2020 | 1.13x | ₩15.36 Billion | ₩13.55 Billion | ₩9.46 Billion | ▲ +176.9% |
| 2019 | 0.41x | ₩9.38 Billion | ₩22.89 Billion | ₩9.08 Billion | ▲ +372.5% |
| 2018 | 0.09x | ₩1.77 Billion | ₩20.47 Billion | ₩1.73 Billion | ▼ -90.5% |
| 2016 | 0.91x | ₩7.96 Billion | ₩8.75 Billion | ₩4.57 Billion | ▲ +81.6% |
| 2015 | 0.50x | ₩3.91 Billion | ₩7.80 Billion | ₩3.86 Billion | ▼ -28.2% |
| 2014 | 0.70x | ₩6.99 Billion | ₩10.02 Billion | ₩6.69 Billion | ▼ -88.4% |
| 2012 | 6.00x | ₩1.54 Billion | ₩256.82 Million | ₩1.24 Billion | ▲ +1330.2% |
| 2011 | 0.42x | ₩1.43 Billion | ₩3.42 Billion | ₩1.20 Billion | — |